Teladoc (TDOC) Form 144: Recent Restricted Shares Proposed for Sale

Rhea-AI Filing Summary

Form 144 filing for Teladoc Health, Inc. (TDOC) shows proposed sale of 4,149 common shares through Fidelity Brokerage Services with an aggregate market value of $31,490.91, to be sold on or about 09/03/2025 on the NYSE. The filer reports acquiring these shares by restricted stock vesting on 09/01/2025, recorded as compensation. The issuer's outstanding shares are listed as 176,690,662.

The filing also discloses sales by the same person in the past three months: 4,174 shares sold 06/03/2025 for $28,842.34 and 2,383 shares sold 09/02/2025 for $18,075.77. The signer certifies no undisclosed material adverse information.

Positive

• Full compliance with Rule 144 disclosure including broker, acquisition details, and past three-month sales
• Transparency on acquisition showing these shares were from restricted stock vesting and recorded as compensation

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider sale of recently vested restricted shares; transaction size is immaterial relative to outstanding stock.

The filing documents a routine disposition of 4,149 newly vested shares executed through a broker. Compared with the listed 176.69 million shares outstanding, this sale is de minimis and unlikely to affect market supply or valuation materially. Recent prior sales totaling 6,557 shares over three months suggest periodic monetization of compensation rather than a large, concentrated divestiture.

Corporate Governance Expert

TL;DR: Disclosure aligns with Rule 144 requirements; acquisition via restricted stock vesting and certification are standard.

The filer reports acquisition by restricted stock vesting and declares the absence of undisclosed material information, consistent with regulatory expectations for Rule 144 notices. The use of a broker and disclosure of past three-month sales provide transparency. No governance or compliance issues are stated in the filing itself.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	4149	31490.91	176690662	09/03/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2025	Restricted Stock Vesting	Issuer			4149	09/01/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
FERNANDO MADEIRA RODRIGUES 155 E 44th Street Floor 17 New York NY 10017	Common	06/03/2025	4174	28842.34
FERNANDO MADEIRA RODRIGUES 155 E 44th Street, Floor 17 New York NY 10017	Common	09/02/2025	2383	18075.77

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the TDOC Form 144 report?

The filing reports a proposed sale of 4,149 common shares to be executed through Fidelity on or about 09/03/2025 with an aggregate market value of $31,490.91.

Who is the seller named in the Form 144 for TDOC?

The sales listed in the filing were made by Fernando Madeira Rodrigues, with past three-month sales also disclosed.

How were the shares acquired according to the filing?

The 4,149 shares were acquired on 09/01/2025 via restricted stock vesting and the consideration is listed as compensation.

What prior sales by the filer are disclosed?

The filer sold 4,174 shares on 06/03/2025 for $28,842.34 and 2,383 shares on 09/02/2025 for $18,075.77.

On which exchange will the proposed sale occur?

The filing specifies the NYSE as the exchange for the proposed sale.